Inclusion Criteria:

1. Hospital inpatients over the age of 20 years and under the age of 75 years, male or
female.

2. Patients who are diagnosed as primary or recurrent malignant intracranial tumors
(Grade III or Grade IV gliomas defined by the World Health Organization [WHO]
classification), including anaplastic astrocytomas, anaplastic oligodendrogliomas,
anaplastic ependymal tumors or glioblastoma multiforme.

3. Suitable for gross total resection on the basis of imaging studies from doctor's
point of view

4. Karnofsky Performance Scale (KPS) ≥ 60 for newly diagnosed tumor

5. KPS ≥ 70 for recurrent tumor

6. Life expectancy at least 3 months

7. Not pregnant or lactating.

8. Patients willing to participate in the trial and sign written informed consent

Exclusion Criteria:

1. Subject is known, suspected or has history of intolerance or allergy to porphyrin.

2. Renal dysfunction (serum creatinine > 1.5 mg/dL)

3. PT/PTT greater than 1.5 times upper limit of normal (ULN)

4. Bilirubin and liver function tests (LFTs) greater than 2 times ULN

5. Alkaline phosphatase greater than 3 times ULN

6. γ-GT greater than 3 times ULN

7. Severe cardiac disease, e.g. angina pectoris, myocardial infarction, cardiac
arrhythmia, congestive heart failure (New York Heart Association Functional
Classification III and IV).

8. Febrile illness and total leukocyte count < 3,000/µL and/or platelet count <
80,000/µL.

9. Implantable electronic medical device such as a pacemaker, life-sustaining electronic
medical device such as an artificial heart-lung machine, contact type electronic
medical device such as an electrocardiograph, others such as an artificial middle
ear, artificial inner ear, metal artificial cardiac valve and gold haemostatic clip.

10. Organ transplant.

11. History or evidence of severe illness or any other condition which would make the
patient, in the opinion of the investigator unsuitable for the study.

12. Significant alcohol, drug or medication abuse as judged by the investigator.

13. History of treatment with any investigational drug within four weeks before the start
of study.

14. Tumors located within the cerebellum or brainstem